
Aptose Biosciences Secures $26M Financing Boost for AML Innovations: Strategic Growth Ahead
Aptose Biosciences has secured $26 million in financing, empowering the company to advance its tuspetinib-based therapies for acute myeloid leukemia (AML). This strategic funding maneuver








